| 79.20 Delayed Data As of Feb 21 |  -1.90 / -2.34%Today’s Change | 20.10 Today|||52-Week Range 300.00 | +12.28% Year-to-Date |
| What Investors Need to Know About Investing in Marijuana Stocks Feb 21 / Zacks.com - Paid Partner Content | Pot Stocks: Who Has the Best Earnings Chart? Feb 12 / Zacks.com - Paid Partner Content |
| Tilray's Deal to Buy Hemp Food Maker Bolsters Marijuana ETF Feb 21 / Zacks.com - Paid Partner Content | Tilray, Inc. (TLRY) Stock Sinks As Market Gains: What You Should Know Feb 08 / Zacks.com - Paid Partner Content |
| Tilray, Inc. (TLRY) Stock Sinks As Market Gains: What You Should Know Feb 15 / Zacks.com - Paid Partner Content | Tilray (TLRY) to Report Q4 Earnings: What's in the Cards? Feb 08 / Zacks.com - Paid Partner Content |
| 4 Reasons Why Marijuana Stocks & ETFs Could Be on a High in 2019 Feb 15 / Zacks.com - Paid Partner Content | Will Q4 Results Continue to Fuel Momentum in Marijuana ETF? Feb 08 / Zacks.com - Paid Partner Content |
| Previous close | 81.10 |
| Today’s open | 81.48 |
| Day’s range | 78.41 - 83.10 |
| Volume | 2,177,003 |
| Average volume (3 months) | 2,958,055 |
| Market cap | $7.1B |
| Earnings growth (last year) | -291.93% |
| Earnings growth (this year) | -- |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | +62.43% |
| P/E ratio | NM |
| Price/Sales | -- |
| Price/Book | -- |
| Today’s change | Today’s % change | |
|---|---|---|
| NBIXNeurocrine Bioscienc... | -2.05 | -2.58% |
| EXASExact Sciences Corp | -0.35 | -0.42% |
| BLUEbluebird bio Inc | -6.20 | -4.65% |
| NKTRNektar Therapeutics | -2.77 | -6.44% |
| Next reporting date | March 19, 2019 |
| EPS forecast (this quarter) | -$0.18 |
| Annual revenue (last year) | $20.5M |
| Annual profit (last year) | -$7.8M |
| Net profit margin | -38.02% |
Sector Health Technology |
Industry Biotechnology |
President, Chief Executive Officer & Director Brendan Kennedy |
Executive Vice President- Operations Greg Christopher |
Corporate headquarters Nanaimo, British Columbia |
